Etiometry Platform vs MyoVista wavECG

A cardiology clinic that wants a 12-lead resting ECG is HeartSciences' buyer, and an ICU team that wants risk indices is Etiometry's. The two purchases do not overlap. The wavECG was cleared in October 2026 (K260005) without the AI-ECG algorithm, and the company says it does not intend to commercialize the device without a cleared algorithm and gives no timeline. The vendor's footer states its AI-ECG products are not commercially available in the United States. The vendor describes MyoVista Insights as hosting third-party AI-ECG results, and the homepage links an Epic showroom listing. A business combination with Fortitude Mining Holdings is expected to close in the fourth quarter of 2026.

On the ICU side, Etiometry's latest clearance, K254066 in April 2026, is a Cardiogenic Shock Tool. The vendor lists its four risk indices separately, and the oxygen-delivery index covers adults 18 and over not on mechanical circulatory support. Pricing runs through a demo form.